| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Bis-PEG11-NHS ester is a linker molecule and does not have a specific biological target. It is used as a tool in chemical biology and drug delivery to conjugate proteins, peptides, or other molecules. The NHS ester groups react with primary amines to form stable amide bonds, while the PEG spacer provides hydrophilicity and flexibility. As a PROTAC linker, it is used to connect a target protein ligand to an E3 ubiquitin ligase ligand. The compound's primary function is to facilitate bioconjugation rather than to modulate a specific biological target.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
In vitro, Bis-PEG11-NHS ester is used as a reagent for bioconjugation reactions. Its activity is assessed by its ability to efficiently crosslink amine-containing molecules, such as proteins or peptides. The compound's hydrophilicity, imparted by the PEG spacer, enhances its solubility in aqueous buffers, facilitating reactions in biological systems. The efficiency of the crosslinking reaction can be monitored by various analytical techniques, such as SDS-PAGE or mass spectrometry. |
| ln Vivo |
In vivo, Bis-PEG11-NHS ester is not typically used as a therapeutic agent itself but as a component in the synthesis of therapeutic molecules, such as PROTACs or antibody-drug conjugates. Its in vivo behavior is determined by the properties of the conjugate it is incorporated into. The hydrophilic PEG spacer can improve the pharmacokinetic properties of the conjugate by increasing its solubility and reducing immunogenicity.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Bis-PEG11-NHS ester as it is not a biologically active compound that targets enzymes or receptors. Its function is purely chemical, serving as a crosslinking reagent. Any biological activity would be associated with the molecules it is conjugated to. Therefore, standard biochemical assays for target engagement are not relevant for this compound.
|
| Cell Assay |
In vitro cellular assays for Bis-PEG11-NHS ester are typically not performed, as it is a chemical linker rather than a drug candidate. However, when used in the synthesis of PROTACs or other bioconjugates, the resulting molecules may be tested in cellular assays to evaluate their biological activity. The linker's role is to enable the formation of these active molecules, and its properties can influence the activity of the final conjugate.
|
| Animal Protocol |
In vivo animal experiments are not typically performed with Bis-PEG11-NHS ester alone. Instead, the compound is used to synthesize bioconjugates that are then tested in animal models. The pharmacokinetics and efficacy of the final conjugate are evaluated, and the linker's properties may influence these parameters. The PEG spacer can improve the conjugate's half-life and reduce its immunogenicity in vivo.
|
| References |
| Molecular Formula |
C34H56N2O19
|
|---|---|
| Molecular Weight |
796.810452461243
|
| Exact Mass |
796.347
|
| CAS # |
123502-57-8
|
| PubChem CID |
123132043
|
| Appearance |
Colorless to light yellow oil
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
786.0±70.0 °C at 760 mmHg
|
| Flash Point |
429.1±35.7 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.518
|
| LogP |
-7.09
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
55
|
| Complexity |
983
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)ON1C(CCC1=O)=O)=O)N1C(CCC1=O)=O
|
| InChi Key |
HOIRLEGKHJCOKZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H56N2O19/c37-29-1-2-30(38)35(29)54-33(41)5-7-43-9-11-45-13-15-47-17-19-49-21-23-51-25-27-53-28-26-52-24-22-50-20-18-48-16-14-46-12-10-44-8-6-34(42)55-36-31(39)3-4-32(36)40/h1-28H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2550 mL | 6.2750 mL | 12.5500 mL | |
| 5 mM | 0.2510 mL | 1.2550 mL | 2.5100 mL | |
| 10 mM | 0.1255 mL | 0.6275 mL | 1.2550 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
